Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer
Introduction
Cisplatin-based concurrent chemoradiotherapy (CCRT) has become the standard treatment for bulky and locally advanced cervical cancer [1]. However, the disease course and appropriate salvage treatments of patients with residual cervical tumor following definitive CCRT remain undefined. By reference to preoperative CCRT results due to a lack of reports after definitive CCRT, as many as 30%–65% of patients still have residual disease after preoperative CCRT [2], [3]. Completion surgery following preoperative CCRT to eliminate potential residual disease and obtain better outcomes has been attempted, but the results did not indicate a survival benefit [4], [5]. Another possible approach is additional chemotherapy, but its role also remains inconclusive [6].
Several imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), can be used to assess the tumor response after CCRT in cervical cancer. MRI is more effective than CT for evaluating the response and extents of disease after CCRT [7], and PET is more useful for measuring tumor metabolism than MRI. However, the appropriate timing of the use of imaging modalities to evaluate the tumor response varies from 1 to 2 months after treatment completion, and PET is often done at 3 months post completion of treatment according to investigators at Washington university [3], [8], [9], [10].
In our institution, pelvic MRI has routinely been performed as a baseline evaluation before CCRT, prior to brachytherapy, and at 3 months after the completion of CCRT. In the present study, the authors retrospectively reviewed the disease courses in women with residual disease detected by post-treatment MRI to compare the prognosis according to salvage treatment and to identify prognostic factors related to survival.
Section snippets
Methods
From 1998 to 2013, 545 consecutive women with biopsy-proven, International Federation of Gynecology and Obstetrics (FIGO) stage IB1 to IVA uterine cervical cancer were treated with curative radiotherapy (RT). Because 52 were lost to follow-up, post-treatment MRI data were available in 493 women. Of the 493 patients, 384 achieved a complete response, 13 had progressive disease outside of the RT field, and 96 had residual tumors. Of the 96 women with residual disease, 53 met the following
Results
The characteristics of the 53 women analyzed in this study are listed in Table 1. Eight patients (15.1%) had non-squamous cell carcinoma: five had adenocarcinoma, one had adenosquamous, one had glassy cell carcinoma, and one had poorly differentiated carcinoma. The size of the primary tumor ranged from 2.7 to 10.0 cm (median, 5.0 cm). The characteristics of the residual disease based on post-treatment MRI are summarized in Table 2. The size of the residual tumor ranged from 0.3 to 4.6 cm (median,
Discussion
In the present study, we analyzed the disease courses and patterns of failure in cervical cancer patients with residual disease on post-treatment MRI, finding that about 60% of patients remained progression free. In patients with disease progression after CCRT, the incidences of local and distant progression were similar. Furthermore, more than half of further disease progression occurred within 1 year from the initial CCRT. Although salvage surgery may be helpful to evaluate pathologic
Conflict of interest statement
The authors have no conflict of interest to report.
Acknowledgement
This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (NRF-2016R1C1B2012823).
References (21)
- et al.
Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis
Gynecol. Oncol.
(2014) - et al.
Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery
Gynecol. Oncol.
(2010) - et al.
Evaluation and impact of residual disease in locally advanced cervical cancer after concurrent chemoradiation therapy: results of a multicenter study
Eur. J. Surg. Oncol.
(2013) - et al.
Completion surgery or not after concurrent chemoradiotherapy for locally advanced cervical cancer?
Eur. J. Obstet. Gynecol. Reprod. Biol.
(2011) - et al.
Preoperative chemoradiotherapy in locally advanced cervical cancer: long-term outcome and complications
Gynecol. Oncol.
(2005) - et al.
Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer)
Gynecol. Oncol.
(2006) - et al.
Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma
Gynecol. Oncol.
(2006) - et al.
Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer
Radiother. Oncol.
(2011) - et al.
Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study
Radiother. Oncol.
(2012) - et al.
The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer
Anticancer Res.
(2013)
Cited by (0)
- 1
Ja Young Kim and Sang Jun Byun contributed equally to this work and are considered co-first authors.